Renee Aguiar-Lucander
Chief Executive Officer

Hello, everybody. I think it's now 9:00. So we're going to try and kick off reasonably on time. And I want to welcome you all to this Capital Markets Day for Hansa Biopharma [indiscernible]. I'm going to introduce a little bit of the people who are here. But first of all, obviously, you should pay appropriate -- take appropriate caution and refer to any kind of regulatory filings. There will be kind of forward-looking statements made during this presentation. So this is the agenda for the day.

And I'm truly delighted that we've been able to bring you such a distinguished panel of experts who are here to share their insights and experiences. We'll cover the top line data from our European confirmatory study, the recently presented data at ATC of our Phase III ConfIdeS study. And then we will also have very exciting outcomes from real-world experience in France, reflecting what dedicated physicians have achieved there with Idefirix who is conditionally approved there. We'll follow up with insights and viewpoints from the experts in the field of HLA profiling, crossmatching and delisting. It is a critical component of transplants. And I will tell you that having had the opportunity to sit through quite a few sessions at ATC that delves into the